Genetic Technologies Stock Analysis

Genetic Stock Analysis Notes

The book value of the company was currently reported as 0.04. The company recorded a loss per share of 0.15. Genetic Technologies last dividend was issued on the 15th of August 2019. The entity had 1:5 split on the 14th of December 2023. Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage peoples health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia. Genetic Tech operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 52 people. To learn more about Genetic Technologies call Eutillio Buccilli at 61 3 8412 7000 or check out https://genetype.com.

Genetic Technologies Investment Alerts

Genetic Technologies Upcoming and Recent Events

Genetic Largest EPS Surprises

View All Earnings Estimates

Genetic Stock Institutional Investors

Note, although Genetic Technologies' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Genetic Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.94 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Genetic Technologies's market, we take the total number of its shares issued and multiply it by Genetic Technologies's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Genetic Profitablity

The company has Profit Margin (PM) of (1.24) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.06) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.06.

Management Efficiency

Genetic Technologies has return on total asset (ROA) of (0.5271) % which means that it has lost $0.5271 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6047) %, meaning that it created substantial loss on money invested by shareholders. Genetic Technologies' management efficiency ratios could be used to measure how well Genetic Technologies manages its routine affairs as well as how well it operates its assets and liabilities. As of April 19, 2024, Return On Tangible Assets is expected to decline to -1.26. In addition to that, Return On Capital Employed is expected to decline to -1.04. At present, Genetic Technologies' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 10.6 M, whereas Total Current Assets are forecasted to decline to about 11.7 M.

Technical Drivers

As of the 19th of April, Genetic Technologies retains the Market Risk Adjusted Performance of 0.3865, risk adjusted performance of 0.0392, and Downside Deviation of 5.69. Genetic Technologies technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for Genetic Technologies, which can be compared to its competitors. Please check out Genetic Technologies maximum drawdown, and the relationship between the information ratio and downside variance to decide if Genetic Technologies is priced fairly, providing market reflects its last-minute price of 2.32 per share. Please also validate Genetic Technologies total risk alpha, which is currently at (0.25) to confirm the company can sustain itself at a future point.

Genetic Technologies Price Movement Analysis

Genetic Technologies Insider Trading Activities

Genetic Technologies Predictive Daily Indicators

Genetic Technologies Corporate Filings

Genetic Technologies Forecast Models

Genetic Technologies' time-series forecasting models are one of many Genetic Technologies' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Genetic Technologies' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Genetic Technologies prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Genetic shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Genetic Technologies. By using and applying Genetic Stock analysis, traders can create a robust methodology for identifying Genetic entry and exit points for their positions.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genetic Technologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Genetic Stock refer to our How to Trade Genetic Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

When running Genetic Technologies' price analysis, check to measure Genetic Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genetic Technologies is operating at the current time. Most of Genetic Technologies' value examination focuses on studying past and present price action to predict the probability of Genetic Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genetic Technologies' price. Additionally, you may evaluate how the addition of Genetic Technologies to your portfolios can decrease your overall portfolio volatility.

Is Genetic Technologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genetic Technologies. If investors know Genetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genetic Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Genetic Technologies is measured differently than its book value, which is the value of Genetic that is recorded on the company's balance sheet. Investors also form their own opinion of Genetic Technologies' value that differs from its market value or its book value, called intrinsic value, which is Genetic Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genetic Technologies' market value can be influenced by many factors that don't directly affect Genetic Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Genetic Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Genetic Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genetic Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.